Biosense Webster to Showcase Advanced Ablation Technologies for Electrophysiologists at HRS 2009

Diamond Bar, CA .— Biosense Webster, Inc., the worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase its portfolio of advanced technologies treating abnormal heart rhythms during the Heart Rhythm Society’s (HRS) 30th Annual Scientific Sessions. Heart Rhythm 2009, the leading conference for electrophysiologists, will be held in the Boston Convention and Exhibition Center from May 13-16, 2009.

A special focus will be on the NaviStar® ThermoCool® Catheter for atrial fibrillation, the first and only ablation catheter in the U.S. to be approved for the treatment of Afib. In the U.S., NaviStar® ThermoCool® Catheters are approved for drug refractory recurrent symptomatic paroxysmal AFib, when used with CARTO® Systems (excluding the NaviStar® RMT ThermoCool® Catheter). The NaviStar® ThermoCool® Catheter was approved for this indication by the U.S. Food and Drug Administration in February 2009.

Complete one-year follow-up data from the NaviStar® ThermoCool® Catheter clinical trial in atrial fibrillation (AFib) will be presented on Thursday, May 14th during the Late Breaking Clinical Trials session.

“This is our first major medical conference since NaviStar® ThermoCool® Catheter received its approval in February and we look forward to speaking to electrophysiologists about benefits in sustained patient outcomes,” said Shlomi Nachman, Worldwide President, Biosense Webster Inc. “We are deeply committed to pioneering innovative and complementary solutions that help electrophysiologists improve patient outcomes and streamline procedural workflow.”

Biosense Webster will also preview the Carto® 3 System, the company’s next generation 3-D navigation platform. The Carto® 3 System received European CE Mark approval in November 2008, and is currently under 510(k) review at the U.S. Food and Drug Administration for use in the U.S.

This year’s booth showcases the company’s cutting-edge brand identity and includes multiple digital tools that highlight the broad array of Biosense Webster’s AFib solutions. The digital media reflecting pool, a center piece of the exhibit, will introduce visitors to the new Afib AllianceSM program, which integrates a host of educational programs, patient education, unique practice management information and tools.

“Our presence at this year at HRS09 is tremendous,” said Nachman. “The new ‘look and feel’ of our booth is exciting and unique and conveys our passion and excitement about our products and our partnership with electrophysiologists to advance treatment options.”

The Biosense Webster exhibit will be at booth #429 at the Boston Convention and Exhibition Center.